Optimal Add-On Medication Strategy for Schizophrenia

Clinical Reasoning for Aripiprazole Augmentation

The American College of Psychiatry recommends aripiprazole augmentation for patients with schizophrenia who have inadequate response to olanzapine, as it improves negative symptoms with a standardized mean difference of −0.41 (95% CI −0.79 to −0.03, p = 0.036) 1
The combination of olanzapine with aripiprazole shows superior outcomes compared to olanzapine monotherapy, with reduced psychiatric hospitalization risk (HR 0.86, 95% CI 0.79–0.94) 2
Aripiprazole offers metabolic benefits by potentially counteracting olanzapine's weight gain and metabolic syndrome through its partial D2 agonist properties 1

The National Institute of Mental Health recommends clozapine monotherapy for treatment-resistant schizophrenia, which is defined as inadequate response to at least two different antipsychotics at adequate doses for 4-6 weeks each 3
Clozapine is the only antipsychotic with documented superiority for treatment-resistant schizophrenia, showing efficacy in 34% of patients who fail other antipsychotics 3
The target clozapine plasma level for therapeutic response is at least 350 ng/mL, potentially increasing to 550 ng/mL if inadequate response at lower levels 4

The American Psychiatric Association recommends documenting baseline movement disorders to distinguish from medication-induced effects before starting aripiprazole 5
Metabolic parameters such as BMI, waist circumference, blood pressure, HbA1c, lipids, and liver function should be checked before starting aripiprazole 1
Akathisia should be assessed weekly during dose escalation, and worsening agitation or activation should be monitored, which may indicate the dose is too high 2
Symptom response should be reassessed at 6-8 weeks using structured assessment of positive and negative symptoms, and metabolic parameters should be repeated at 3 months to assess impact on olanzapine-induced metabolic effects 3, 5